Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)


About this study

The purpose of this study is to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 45 and ≤ 75 years old AND
  • AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström’s Macroglobulinemia, or another blood cancer.
  • For participants with a strong family history (2 relatives with blood cancers, their first- and second-degree relatives will be allowed to participate if 18 years or older.

Exclusion Criteria:

  • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
  • Persons diagnoses with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström’s Macroglobulinemia.
  • First degree relatives would not need to be identified by the participant. 
  • We will include all special populations who fall within the eligible high-risk age range,  ≥ 40 and ≤ 75 including adults unable to consent, pregnant women, and prisoners.  These populations will not be excluded as this is a non-therapeutic study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015


More information


Publications are currently not available

Mayo Clinic Footer